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Yale scientists played a pivotal role in the discovery of Lyme disease and are credited as the
first to recognize, name, characterize, and treat the affliction. Today, Lyme disease is the
most commonly reported vector-borne illness in the United States, affecting approximately
20,000 people each year, with the incidence having doubled in the past 10 years [1]. Lyme
disease is the result of a bacterial infection transmitted to humans through the bite of an in-
fected deer tick, which typically results in a skin rash at the site of attack. While most cases,
when caught early, are easily treated by antibiotic therapy, delayed treatment can lead to se-
rious systemic side effects involving the joints, heart, and central nervous system. Here we
review Yale’s role in the discovery and initial characterization of Lyme disease and how
those early discoveries are crucial to our current understanding of the disease.
Recognition — Lyme ARthRitis
The Yale Team
In the early fall of 1975, two mothers
from Old Lyme, Connecticut, desperately
sought medical help regarding the mysteri-
ous outbreak of arthritis and juvenile arthri-
tis in their families and town. In the face of
unexplainable symptoms and unsatisfying
diagnoses, they reached out to the Con-
necticut State Department of Health and the
Yale School of Medicine, sparking an in-
vestigation  that  would  culminate  in  the
characterization  of  what  is  now  widely
known as Lyme disease [2].
The initial studies carried out in Lyme,
Connecticut, and two surrounding towns on
the eastern bank of the Connecticut River
in New London County were led by Allan
C. Steere, MD, and Stephen E. Malawista,
MD, from the Rheumatology section of the
Yale School of Medicine, in conjunction
To whom all correspondence should be addressed: Shana Elbaum-Garfinkle, 
226 Whitney Bass 228, New Haven, CT; Tele: 203-432-5647; Fax: 203-432-5175; 
E-mail: shana.elbaum@yale.edu.
†Abbreviations: ECM, erythema chronicum migrans; EM, erythema migrans; Osps, outer
surface proteins; TROSPA, tick receptor protein.
Keywords: Lyme disease; Lyme arthritiswith David R. Snydman, MD, and Francis
M. Steele, PhD, from the Connecticut State
Department of Health, among others. Dr.
Steere, the first author of the study, was a
first-year  fellow  in  rheumatology  at  the
time.  Dr.  Malawista,  then  Head  of  the
Rheumatology Section at Yale, continues to
pioneer Lyme disease research at Yale. 
The Investigation
In December 1975, Steere and Malaw-
ista led a surveillance study [3] to investigate
the cause of a sudden outbreak of rheuma-
toid arthritis in and around Lyme. The study
focused on the three contiguous towns of Old
Lyme, Lyme, and East Haddam, where 51
residents  were  diagnosed  with  juvenile
arthritis or arthritis of unknown cause (39
children and 12 adults) out of a total popula-
tion of 12,000. The investigation consisted
of thorough physical examinations and blood
work of each patient on site at Yale. Addi-
tionally, detailed patient histories were col-
lected through interviews with each patient’s
local physician and family members.
While the early physical examinations
and laboratory tests revealed nothing out of
the ordinary, the interview aspect was sur-
prisingly  informative.  Approximately  25
percent of the patients in the study reported
a skin lesion with an expanding bull’s-eye
pattern four or more weeks preceding the
onset of arthritic symptoms. The authors
found this to be particularly intriguing, as
the lesion matched the description of ery-
thema chronicum migrans (ECM), or ery-
thema migrans (EM), a lesion previously
reported in Europe that was thought to be a
result of an infectious agent but had never
before been associated with arthritis [4].
The mysterious arthritis also emerged
in interesting patterns geographically and
temporally. Most of the patients lived in
close proximity within the towns ― several
children lived on a particular road, and the
arthritis afflicted several members from the
same family. The patients also exclusively
lived in the rural wooded areas of town, with
no cases present in the town centers. No-
tably, there was also a unique temporal clus-
tering to the symptoms, with the majority of
onset occurring from June through Septem-
ber. Rheumatoid arthritis, a known autoim-
mune disease leading to inflammation of the
joints, had never before been, nor would it
have been, expected to cluster geographi-
cally or temporally in this way. 
The Skin Lesion-EM
The term erythema migrans (EM) was
first mentioned in a presentation at the 1909
meeting of the Swedish Dermatological So-
ciety in Stockholm by Arvid Afzelius [2].
EM, also reported as erythema chronic mi-
grans (ECM),  was  sometimes  associated
with a tick bite and was accompanied by
nerve pain, paralysis, or meningitis. In Eu-
rope, doctors believed that EM might be
caused by a bacterium, and penicillin and
other antibiotics were moderately effective
at treating it. This connection between ticks
and EM led Steere and Malawista to hypoth-
esize that Lyme disease might be transmitted
by the bite of an arthropod such as a tick. 
However, in the United States, there was
little experience with EM, and in the Euro-
pean cases, EM never presented with arthritis.
Intrigued by the EM lesion described by pa-
tients in their first study, Steere and Malaw-
ista eagerly awaited the next “high season.”
Indeed, during the summer of 1976, 30 new
patients were identified, a survey of which
strengthened the connection between the ini-
tial presentation of EM and the later devel-
opment of arthritis [5]. The Yale team thus
officially declared EM as the initial mark of
infection and as the diagnostic hallmark of
“Lyme arthritis,” the initial name given for
the disease by Yale investigators [6].
The Tick
While Steere and Malawista suggested
the tick as the vector of Lyme arthritis as
early as 1976 [3,5,6], in 1978 they showed
epidemiological evidence for a tick vector
by expanding their surveillance of the Lyme
area across the Connecticut River [7]. They
found that the incidence of Lyme arthritis
was 30 times greater on the east side of the
river, where Lyme is located, than it was on
the west side, similar to the difference in
deer and deer tick distribution in the area [8].
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deed are the transmission vector of the in-
fectious agent in Lyme disease. In the United
States, Lyme disease is transmitted by the
deer tick, or Ixodes scapularis, member of
the Ixodes family. Other related Ixodes ticks
have been found in Europe and Asia. The
Ixodes tick can become infected at any point
of its 2-year lifespan, which consists of three
distinct stages — larvae, nymph, and adult
[9,10]. The tick’s survival depends on a feed-
ing or “blood meal” at each stage of its life.
The larvae hatched in late summer feed on
small  animals  such  as  the  white-footed
mouse  that  can  be  infected  but  remain
asymptomatic, serving as a continuous re-
source for infection. The larvae then molt
into nymphs who feed again the following
spring to early summer. Transmission to hu-
mans typically occurs by ticks in this stage,
as increases in outdoor activity coincides
with the nymph feeding cycle. The small size
of the nymph, about the size of a poppy seed,
allows them to go unnoticed. Furthermore, it
has been shown that a tick must feed for 48
or more hours to transmit infection. In the
fall, nymphs molt into adult ticks, which then
feed on large animals, deer in particular.
Adult ticks, which may actually mate on the
deer itself, are transmitted by deer to the sur-
roundings, usually leafy areas, where new
larvae are hatched the following summer.
Deer thus play an important role in the
tick life cycle by supplying a blood meal and
potentially serving as a mating ground for
adult ticks. Accordingly, the recent explo-
sion of the United States deer population is
thought to be responsible for the dramatic
increase in the instances of Lyme disease,
particularly in the Northeast [11]. Efforts to
decrease the prevalence of Ixodes scapularis
ticks and Lyme disease through the control
of deer populations have proven successful
[12] and is thought to be one possible Lyme
disease prevention strategy. 
Lyme DiseAse — moRe thAn
ARthRitis
To Steere and Malawista, it soon be-
came clear that “Lyme arthritis” was actu-
ally only a small piece of a larger puzzle.
Now that the EM skin lesion was confirmed
as the initial mark of infection, the Yale team
made a major effort to inform and educate
the area near Lyme. The Yale team also
asked local healthcare providers to refer pa-
tients to them soon after infection, enabling
them to further characterize the disease and
onset. As the result of these further studies,
the team reports that Lyme disease can man-
ifest in a variety of systemic ways, includ-
ing those involving the nervous system [13],
the heart [14], and the joints [15-19].   
In 1984, the Yale School of Medicine
brought together Lyme disease researchers
from all over the world at the First Interna-
tional Conference on Lyme Disease in New
Haven [10,20]. For the first time, profession-
als from a range of disciplines, including
rheumatology,  immunology,  dermatology,
and neurology, as well as public health offi-
cials and practicing physicians were gathered
in recognition of this new complex and sys-
temic disease. In 1985, Steere and Malawista
were awarded the Ciba-Geigy International
League Against Rheumatism Prize, an honor
given once every 4 years, for the discovery
and elucidation of Lyme disease. A group of
Yale scientists continue to lead research ef-
forts in various aspects of Lyme disease, in-
cluding disease epidiomology (Durland Fish,
PhD, and Eugene D. Shapiro, MD, from the
Yale School of Public Health); the life cycle
of the bacterium (Erol Fikrig, MD, Infectious
Diseases, Yale School of Medicine); and in-
flammation and immunity (Linda Bockenst-
edt,  MD,  and  Stephen  Malawista,  MD,
Rheumatology, Yale School of Medicine).
Clinical Features
Today, Lyme disease is clinically de-
scribed as either “early” or “late.” Early
Lyme disease initially presents itself with
the characteristic bull’s-eye patterned lesion,
erythema migrans (EM). This lesion can last
anywhere  from  several  days  to  several
weeks [21] and is most often accompanied
by severe fatigue, myalgia, arthralgias, re-
gional lymphodenopathies, and headaches
or fever. The initial EM lesion can some-
times spread to produce smaller secondary
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Patients may further develop neurologic,
cardiac, and rheumatogical symptoms in the
early stage, the exact causes of which are
still not fully understood. 
One of the most common features of
late Lyme disease is arthritis, particularly
asymmetric oligoarticular arthritis, involv-
ing large joints such as the knees. Arthritis
arises when an inflammatory response oc-
curs in the synovial tissue between the joints
and leads to painful swelling in the affected
area.
tReAtment
In  1977,  in  the  journal  Science [5],
Steere and Malawista reported the presence
of common antibodies extracted from pa-
tients experiencing an active EM lesion or
active arthritis, thereby suggesting a com-
mon origin for these two clinical symptoms.
While it would be several years before the
infectious agent that causes Lyme disease
would be isolated, the Yale team had grow-
ing evidence for the role of a bacterial infec-
tion  in  the  disease.  In  1980,  Steere  and
Malawista determined that antibiotic treat-
ment “shortens the duration of ECM and
may prevent or attenuate subsequent arthri-
tis” [22]. The study consisted of 113 patients
presenting the EM lesion. Half of the group
did not receive treatment, while the other half
were treated with antibiotics. In patients who
did not receive antibiotics, the EM lesion and
associated symptoms resolved within a me-
dian of 10 days after the initial visit. Those
patients receiving antibiotic treatment expe-
rienced significantly faster resolution of EM,
with a median of duration of 4 days. Fur-
thermore, significantly fewer patients in the
antibiotic group went on to develop arthritis
compared to patients in the control group.
Antibiotic therapy is still the major line of
treatment for Lyme disease [23]. 
The Infectious Agent: B. burgdorferi
In 1982, Burgdorfer and colleagues iso-
lated the infectious agent that causes Lyme
disease that now bears his name: Borrelia
burgdorferi [24]. The genus Borrelia is a
member of the family Spirochaetacaea, also
known as spirochetes, which are Gram-neg-
ative bacterium characterized by a wavelike
body and flagella [21]. Burgdorfer and col-
leagues collected and dissected hundreds of
Ixodes ticks from Shelter Island, New York
(another location with a high prevalence of
Lyme disease) and found that most of them
contained spirochetes, specifically in the
mid gut region. They further characterized
the spirochetes with dark field and electron
microscopy. Finally, indirect immunofluo-
rescence revealed that antibodies extracted
from serum of Lyme disease-infected pa-
tients reacted positively with the spirochete,
while serum from control patients did not —
thereby  confirming  the  link  between  the
tick-derived spirochete and Lyme disease. In
the United States, Lyme disease is primarily
caused by the spirochete Borrelia Burgdor-
feri sensu stricto. Other related genospecies
of Borrelia such as B. garinii, and B. afzelii
have been identified in Europe and Asia.
Outer Surface Proteins
B. burgdorferi’s persistence inside the
tick and transmission to its human host are
thought to be a product of altered expression
of outer surface proteins (Osps). When in-
side the tick host, expression of OspA en-
ables B. burgdorferi to persist in the gut.
More specifically, Erol Fikrig, MD, and col-
leagues at Yale have found that a tick recep-
tor protein (TROSPA) expressed in the tick
gut is responsible for tight binding to OspA
[25]. During a tick’s blood meal, expression
of OspA is decreased, leading to dissocia-
tion from the gut, and expression of OspC is
increased. OspC is thought to play a role in
migration of the bacterium from the tick’s
gut to its salivary glands [26]. Fikrig and
colleagues, along with Durland Fish, PhD,
from the Yale School of Public Health, have
since shown that the interaction of OspC
with the tick salivary protein Salp15 en-
hances the infectivity of B. burgdorferi in its
new mammalian host [27]. Once inside the
human host, B. burgdorferi induces immune
responses that lead to a variety of symptoms
present in the disease. Vaccines incorporat-
ing OspA, a strong antigen that induces an
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are currently off the market due to compli-
cations [28,29]. 
Diagnosis 
Clear diagnosis of Lyme disease has
been challenging. If the EM rash is present,
then diagnosis is ameliorated, but since not
all patients present with a purely character-
istic rash and sometimes do not notice it in
time, diagnosis remains difficult. Serologi-
cal tests that indirectly test for antibodies
produced against B. burgdorferi are often
used, along with somewhat less accurate
PCR assays. There is some controversy over
misdiagnosis of Lyme disease and even the
existence of long-term chronic Lyme disease
[9,21,30] that is beyond the scope of this ar-
ticle. However, a regimen of antibiotic ther-
apy is typically sufficient in treating the
disease at any stage, with greatest efficacy
seen for patients receiving treatment soon
after the tick bite and associated EM lesion.  
concLusion
The massive efforts taken by Steere and
Malawista toward the investigation of the
clustering of arthritis in Lyme in the late
1970s and early 1980s have led to the dis-
covery of a complex, multifaceted disease.
The results of their studies have laid the
foundation for our current understanding of
the role of the infectious agent, the tick as
vector for infection, the EM skin lesion, and
the systemic clinical symptoms of late onset.
Yale investigators continue to lead the field
of Lyme disease research today.  
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